These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL. Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982 [TBL] [Abstract][Full Text] [Related]
8. Targeting MEK in vemurafenib-resistant hairy cell leukemia. Caeser R; Collord G; Yao WQ; Chen Z; Vassiliou GS; Beer PA; Du MQ; Scott MA; Follows GA; Hodson DJ Leukemia; 2019 Feb; 33(2):541-545. PubMed ID: 30341394 [No Abstract] [Full Text] [Related]
9. Nanomedicine against multidrug resistance in cancer treatment. Gao J; Feng SS; Guo Y Nanomedicine (Lond); 2012 Apr; 7(4):465-8. PubMed ID: 22471716 [No Abstract] [Full Text] [Related]